Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: Comparisons of clinical effectiveness in a randomized trial

Cancer

Volumn 119, Issue 10, 2013, Pages 1784-1791

  Yi, Chin A ^a   Lee, Kyung Soo ^a   Lee, Ho Yun ^a   Kim, Seonwoo ^b   Kwon, O Jung ^a   Kim, Hojoong ^a   Choi, Joon Young ^a   Kim, Byung Tae ^a   Hwang, Hye Sun ^a,c   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Hallym University   (South Korea)

Author keywords

integrated positron emission tomography computed tomography; magnetic resonance imaging positron emission tomography; nonsmall cell lung cancer; TNM staging; whole body imaging

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORACOTOMY;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 84877586065     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28000     Document Type: Article

References (22)

1. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348: 2500-2507.
2. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005; 236: 1011-1019.
3. Blomqvist L, Torkzad MR,. Whole-body imaging with MRI or PET/CT: the future for single-modality imaging in oncology? JAMA. 2003; 290: 3248-3249.
4. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003; 290: 3199-3206.
5. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004; 233: 139-148.
6. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol. 2008; 65: 47-58.
7. Alberts WM,. Diagnosis and management of lung cancer executive summary: ACCP Evidence-Based Clinical Practice Guidelines (2nd edition). Chest. 2007; 132 (3 suppl): 1S-19S.
8. Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008; 248: 632-642.
9. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999; 212: 803-809.
10. Lee HY, Lee KS, Kim BT, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci. 2009; 24: 1132-1138.
11. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters [published online ahead of print February 6, 2012]. Head Neck. 2012.
12. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P,. The IASLC Lung Cancer Staging Project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4: 568-577.
13. Kim YN, Yi CA, Lee KS, et al. A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non-small-cell lung cancer. Eur Radiol. 2012; 22: 1537-1546.
14. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009; 151: 221-228, W-48.
15. Yi CA, Lee KS, Kim B-T, Kwon OJ, Shim YM,. Staging of non-small cell lung cancer with visual correlation of whole body MR imaging and positron emission tomography (MRI/PET): efficacy comparison with integrated PET/CT [abstract VC31-12]. Paper presented at: Radiological Society of North America 95th Scientific Assembly and Annual Meeting; November 29 to December 4, 2009; Chicago, IL.
16. Antoch G, Bockisch A,. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009; 36 (suppl 1): S113-S120.
17. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging. 2010; 37: 1077-1086.
18. Schwenzer NF, Schraml C, Muller M, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology. 2012; 264: 551-558.
19. Pichler BJ, Kolb A, Nagele T, Schlemmer HP,. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010; 51: 333-336.
20. Ratib O, Beyer T,. Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging. 2011; 38: 992-995.
21. Metser U, Golan O, Levine CD, Even-Sapir E,. Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography? J Comput Assist Tomogr. 2005; 29: 554-559.
22. Nogami M, Nakamoto Y, Sakamoto S, et al. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann Nucl Med. 2007; 21: 189-196.